AKUMS Q1 FY27 results at a glance
AKUMS DRUGS AND PHARMA L Q1 FY27 key results metrics| Quarter | Q1 FY27 |
|---|
| Quarter ended | 30 Jun 2026 |
|---|
| Revenue | ₹1,167 cr |
|---|
| Revenue YoY | +13.9% |
|---|
| Operating profit | ₹134 cr |
|---|
| Operating margin | 11.5% |
|---|
| Net profit | ₹100 cr |
|---|
| Net profit YoY | +57.6% |
|---|
| Net profit QoQ | +18.2% |
|---|
| Net margin | 8.6% |
|---|
| Basic EPS | ₹6.53 |
|---|
| TTM revenue | ₹4,502 cr |
|---|
| TTM net profit | ₹292 cr |
|---|
| TTM net margin | 6.5% |
|---|
AKUMS Q1 FY27 results: what the numbers say
AKUMS DRUGS AND PHARMA L (AKUMS) has reported its Q1 FY27 results for the quarter ended 2026-06-30. The company posted revenue of ₹1,167 cr and a net profit of ₹100 cr, translating into earnings per share of ₹6.53.
Compared with the same quarter a year earlier, revenue grew by +13.9% and net profit grew sharply by +57.6%. Profit rising faster than revenue points to better cost control or operating leverage flowing through the P&L.
Operating profit for the quarter stood at ₹134 cr, an operating margin of 11.5% versus 9.0% a year ago — a gain of 2.5 percentage points.
AKUMS quarter-wise results table
Revenue
₹1,167 cr
+13.9% YoY
Net profit
₹100 cr
+57.6% YoY
Operating profit
₹134 cr
+45.2% YoY
AKUMS DRUGS AND PHARMA L (AKUMS) quarter-wise results — revenue, operating profit, net profit, margins, EPS and growth| Quarter | Revenue | Operating profit | Net profit | OPM | Net margin | EPS | Profit YoY | Profit QoQ |
|---|
| Q1 FY272026-06-30 | ₹1,167 cr | ₹134 cr | ₹100 cr | 11.5% | 8.6% | ₹6.53 | +57.6% | +18.2% |
| Q4 FY262026-03-31 | ₹1,158 cr | ₹112 cr | ₹84.61 cr | 9.6% | 7.3% | ₹5.53 | — | +27.6% |
| Q3 FY262025-12-31 | ₹1,160 cr | ₹107 cr | ₹66.32 cr | 9.2% | 5.7% | ₹4.33 | — | +62.6% |
| Q2 FY262025-09-30 | ₹1,018 cr | ₹56.61 cr | ₹40.78 cr | 5.6% | 4.0% | ₹2.66 | — | -35.7% |
| Q1 FY262025-06-30 | ₹1,024 cr | ₹92.05 cr | ₹63.48 cr | 9.0% | 6.2% | ₹4.15 | — | — |
| TTM (last 4 quarters) | ₹4,502 cr | ₹409 cr | ₹292 cr | 9.1% | 6.5% | ₹19.05 | — | — |
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
AKUMS quarterly income statement
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
AKUMS DRUGS AND PHARMA L quarterly income statement| Particulars | Q1 FY272026-06-30 | Q4 FY262026-03-31 | Q3 FY262025-12-31 | Q2 FY262025-09-30 | Q1 FY262025-06-30 |
|---|
| Revenue / Sales | ₹1,167 cr | ₹1,158 cr | ₹1,160 cr | ₹1,018 cr | ₹1,024 cr |
|---|
| Total expenses | ₹1,033 cr | ₹1,046 cr | ₹1,052 cr | ₹961 cr | ₹932 cr |
|---|
| Gross profit | ₹521 cr | ₹497 cr | ₹481 cr | ₹425 cr | ₹442 cr |
|---|
| Operating profit (EBIT) | ₹134 cr | ₹112 cr | ₹107 cr | ₹56.61 cr | ₹92.05 cr |
|---|
| Operating margin | 11.5% | 9.6% | 9.2% | 5.6% | 9.0% |
|---|
| Interest cost | ₹24.76 cr | ₹23.89 cr | ₹23.74 cr | ₹19.9 cr | ₹23.14 cr |
|---|
| Profit before tax | ₹139 cr | ₹121 cr | ₹99.57 cr | ₹65.67 cr | ₹95.65 cr |
|---|
| Tax expense | ₹38.26 cr | ₹39.87 cr | ₹31.89 cr | ₹22.98 cr | ₹30.96 cr |
|---|
| Effective tax rate | 27.5% | 32.9% | 32.0% | 35.0% | 32.4% |
|---|
| Net profit (PAT) | ₹100 cr | ₹84.61 cr | ₹66.32 cr | ₹40.78 cr | ₹63.48 cr |
|---|
| Net profit margin | 8.6% | 7.3% | 5.7% | 4.0% | 6.2% |
|---|
| Basic EPS | ₹6.53 | ₹5.53 | ₹4.33 | ₹2.66 | ₹4.15 |
|---|
| Diluted EPS | ₹6.53 | ₹5.53 | ₹4.33 | ₹2.66 | ₹4.15 |
|---|
AKUMS results growth — YoY and QoQ
Quarterly growth rates, year on year and quarter on quarter| Growth | Q1 FY27 | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 |
|---|
| Revenue YoY | +13.9% | — | — | — | — |
|---|
| Revenue QoQ | +0.8% | -0.1% | +14.0% | -0.6% | — |
|---|
| Operating profit YoY | +45.2% | — | — | — | — |
|---|
| Operating profit QoQ | +19.7% | +4.1% | +89.4% | -38.5% | — |
|---|
| Net profit YoY | +57.6% | — | — | — | — |
|---|
| Net profit QoQ | +18.2% | +27.6% | +62.6% | -35.7% | — |
|---|
| EPS YoY | +57.3% | — | — | — | — |
|---|
| EPS QoQ | +18.1% | +27.7% | +62.8% | -35.9% | — |
|---|
AKUMS annual results history
Full-year performance for AKUMS DRUGS AND PHARMA L, useful for reading each quarter in context.
AKUMS DRUGS AND PHARMA L annual income statement| Particulars | FY262026-03-31 | FY252025-03-31 | FY242024-03-31 | FY232023-03-31 |
|---|
| Revenue / Sales | ₹4,251 cr | ₹4,071 cr | ₹4,020 cr | ₹3,475 cr |
|---|
| Total expenses | ₹3,877 cr | ₹3,760 cr | ₹3,660 cr | ₹3,283 cr |
|---|
| Gross profit | ₹1,703 cr | ₹1,605 cr | ₹1,437 cr | ₹1,167 cr |
|---|
| Operating profit (EBIT) | ₹374 cr | ₹311 cr | ₹360 cr | ₹191 cr |
|---|
| Operating margin | 8.8% | 7.6% | 9.0% | 5.5% |
|---|
| Interest cost | ₹88.62 cr | ₹30.41 cr | ₹50.25 cr | ₹45.97 cr |
|---|
| Profit before tax | ₹382 cr | ₹345 cr | -₹45.28 cr | ₹150 cr |
|---|
| Tax expense | ₹126 cr | ₹1.48 cr | -₹46.07 cr | ₹52.48 cr |
|---|
| Effective tax rate | 32.9% | 0.4% | 101.7% | 34.9% |
|---|
| Net profit (PAT) | ₹255 cr | ₹338 cr | -₹4.04 cr | ₹94.86 cr |
|---|
| Net profit margin | 6.0% | 8.3% | -0.1% | 2.7% |
|---|
| Basic EPS | ₹16.67 | ₹22.60 | ₹-0.28 | ₹6.03 |
|---|
| Diluted EPS | ₹16.67 | ₹22.60 | ₹-0.28 | ₹6.03 |
|---|
Revenue trend and demand read-through
Topline for Q1 FY27 came in at ₹1,167 cr against ₹1,024 cr in Q1 FY26, and ₹1,158 cr in the preceding Q4 FY26 quarter.
On a sequential basis revenue grew +0.8%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹1,033 cr, or 88.5% of revenue, with operating profit grew +45.2% year on year.
Margins, tax and profitability
Net profit of ₹100 cr works out to a net margin of 8.6% compared with 6.2% in the year-ago quarter. Margin expansion of this kind usually reflects a better product or service mix, softer input costs, or tighter overheads.
Below the operating line, AKUMS DRUGS AND PHARMA L reported profit before tax of ₹139 cr, a tax charge of ₹38.26 cr (effective rate 27.5%), interest cost of ₹24.76 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from ₹84.61 cr in Q4 FY26 to ₹100 cr in Q1 FY27, a change of +18.2%.
Trailing twelve months and annual context
Across the trailing four quarters AKUMS DRUGS AND PHARMA L has generated revenue of ₹4,502 cr and net profit of ₹292 cr, a trailing net margin of 6.5%. The trailing view smooths out one-off quarters and is the number most valuation multiples are built on.
On a full-year basis, FY26 revenue was ₹4,251 cr with net profit of ₹255 cr and EPS of ₹16.67, versus the prior year where revenue grew +4.4% and profit declined -24.5%.
What to watch in the next AKUMS quarter
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A sustained run of year-on-year profit growth is what usually drives a re-rating rather than any single quarter.
AKUMS DRUGS AND PHARMA L has not yet intimated its next results date to the exchange. This page refreshes automatically from filings and the board-meeting calendar, so the tables above will reflect the next quarter as soon as it is reported.
All figures here are as reported to the exchanges and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
AKUMS results coverage
No results report published for AKUMS yet — our desk covers each quarter within minutes of the filing.
AKUMS quarterly results FAQs
What were AKUMS DRUGS AND PHARMA L (AKUMS) Q1 FY27 results?
In Q1 FY27 (quarter ended 30 Jun 2026), AKUMS DRUGS AND PHARMA L reported revenue of ₹1,167 cr and net profit of ₹100 cr, a change of +57.6% year on year on +13.9% revenue growth. EPS stood at ₹6.53.
What is AKUMS profit margin in Q1 FY27?
AKUMS DRUGS AND PHARMA L posted a net profit margin of 8.6% and an operating margin of 11.5% in Q1 FY27. On a trailing twelve-month basis, revenue is ₹4,502 cr and net profit ₹292 cr.
Did AKUMS results beat the previous quarter?
AKUMS DRUGS AND PHARMA L net profit changed +18.2% quarter on quarter, from ₹84.61 cr in Q4 FY26 to ₹100 cr in Q1 FY27.
When are AKUMS DRUGS AND PHARMA L (AKUMS) quarterly results?
AKUMS DRUGS AND PHARMA L has not yet intimated its next results date to the exchange. This page updates automatically from the exchange board-meeting calendar.
Where can I see AKUMS latest quarterly results?
Results coverage for AKUMS will appear here as soon as the company reports. Meanwhile you can track live price and technicals on the AKUMS stock page.
What is AKUMS DRUGS AND PHARMA L annual revenue and profit?
For FY26, AKUMS DRUGS AND PHARMA L reported full-year revenue of ₹4,251 cr and net profit of ₹255 cr, with EPS of ₹16.67.
How many quarterly results has AKUMS declared recently?
Past results dates for AKUMS will be listed here from the exchange calendar.
Results dates sourced from the exchange board-meeting calendar; reported figures from company filings, last refreshed 12 Sept 2026. For information only, not investment advice.
